share_log

Yifeng Pharmacy Chain (SHSE:603939) Sheds 4.7% This Week, as Yearly Returns Fall More in Line With Earnings Growth

Yifeng Pharmacy Chain (SHSE:603939) Sheds 4.7% This Week, as Yearly Returns Fall More in Line With Earnings Growth

益豐藥房(上證:603939)本週下跌4.7%,年度回報更符合創業板增長。
Simply Wall St ·  06/10 18:56

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, the Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) share price is up 78% in the last 5 years, clearly besting the market return of around 9.9% (ignoring dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 16% in the last year, including dividends.

一般而言,積極選擇股票的目的是尋找提供高於市場平均回報的公司。雖然積極選擇股票存在風險(需要分散投資),但也可以提供額外的回報。例如,益豐藥房股份有限公司(SHSE:603939)的股價在過去5年中上漲了78%,明顯超過了市場回報率約9.9%(不考慮股息)。然而,最近的回報並不像那樣令人印象深刻,包括股息在內的股票在過去一年中僅回報16%。

Since the long term performance has been good but there's been a recent pullback of 4.7%, let's check if the fundamentals match the share price.

由於長期表現良好,但最近出現了4.7%的回撤,讓我們來檢查一下基本面是否與股價相符。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

在他的文章《格雷厄姆和多德斯維爾超級投資者》中,禾倫·巴菲特描述了股票價格並不總是反映公司價值的合理方式。考慮市場對公司的看法如何發生變化的一個不完美但簡單的方法是將每股收益(EPS)的變化與股價的變動進行比較。股票價格並不總是反映公司價值的合理方式禾倫·巴菲特曾稱,股票價格並不總是合理地反映了企業的價值。檢查市場情緒如何隨時間變化的一種方法是查看公司股價和每股收益(EPS)之間的互動。

Over half a decade, Yifeng Pharmacy Chain managed to grow its earnings per share at 24% a year. The EPS growth is more impressive than the yearly share price gain of 12% over the same period. So one could conclude that the broader market has become more cautious towards the stock.

在半個世紀的時間裏,益豐藥房每股收益增長率達到24%。EPS增長比同期每股股價的漲幅12%更爲引人注目。因此,可以得出結論,整個市場對該股更加謹慎。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

下面可以看到每股收益隨時間的變化情況(通過點擊圖像來查看確切數值)。

earnings-per-share-growth
SHSE:603939 Earnings Per Share Growth June 10th 2024
SHSE:603939每股收益增長2024年6月10日

We know that Yifeng Pharmacy Chain has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.

我們知道,益豐藥房的淨利潤有所提高,但它是否會增長營業收入呢?如果您感興趣,可以查看這份顯示共識收入預測的免費報告。

What About Dividends?

那麼分紅怎麼樣呢?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Yifeng Pharmacy Chain the TSR over the last 5 years was 84%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence!

除了衡量股價回報外,投資者還應考慮總股東回報(TSR)。TSR包括任何分拆或折價融資的價值,以及假設股息被再投資的任何股息。可以說,TSR給出了一種更全面的股票回報圖景。我們注意到,對於益豐藥房而言,過去5年的TSR爲84%,這比上面提到的股價回報要好。而且,毫無疑問,股息支付在很大程度上解釋了這種差異!

A Different Perspective

不同的觀點

We're pleased to report that Yifeng Pharmacy Chain shareholders have received a total shareholder return of 16% over one year. Of course, that includes the dividend. That's better than the annualised return of 13% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Yifeng Pharmacy Chain you should be aware of.

我們很高興地報告,益豐藥房股東在過去一年中獲得了總股東回報16%。當然,這包括股息。這比半個世紀以來的年化回報率13%更好,這意味着近期公司的表現更好。一個樂觀的觀點是,TSR的最近改善表明公司本身正在逐漸變得更好。當然可以考慮市場狀況對股價的不同影響,但有更重要的因素。例如:我們發現了益豐藥房的1個警告標誌,您應該注意。

Of course Yifeng Pharmacy Chain may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,益豐藥房可能不是最好的股票購買選擇。因此,您可能希望查看這些增長股的免費收藏。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論